About event
Dysregulation of fibroblast growth factor signaling is implicated in various diseases, including cancer. Current therapeutics lack specificity, targeting multiple FGFR isoforms and other receptor tyrosine kinases. We identified VZ23, a DNA aptamer with high specificity for FGFR1, effectively inhibiting FGFR1 signaling. By partially resolving the structure of VZ23, we gained fundamental insight into its structural features, enabling the rational design and targeted incorporation of covalent modifications to enhance its stability and biological activity. Our findings highlight DNA aptamers as a promising alternative to current therapeutics for targeting FGFR1-related disorders.
The lecture is part of the Structural Biology Seminar Series. PhD candidates, postdocs, and research group leaders from the structural biology field present their newest research results to the MUNI scientific community. Ideal space for knowledge sharing, networking and professional growth.
